UBS AM
MACK

UBS AM’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

UBS AM’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-13,633
Closed -$133K – 2577
2017
Q2 		$133K Buy
13,633
+4,446
+48% +$90.8K ﹤0.01% 2311
2017
Q1 		$223K Buy
9,187
+3,836
+72% +$96K ﹤0.01% 2139
2016
Q4 		$172K Sell
5,351
-4,194
-44% -$179K ﹤0.01% 2161
2016
Q3 		$477K Sell
9,545
-33,554
-78% -$1.39M ﹤0.01% 2007
2016
Q2 		$1.83M Sell
43,099
-123,245
-74% -$6.71M ﹤0.01% 1393
2016
Q1 		$11M Buy
166,344
+5,588
+3% +$292K 0.01% 826
2015
Q4 		$9.99M Sell
160,756
-5,344
-3% -$376K 0.01% 870
2015
Q3 		$11.1M Buy
166,100
+54,488
+49% +$4.45M 0.01% 844
2015
Q2 		$10.9M Buy
111,612
+1,004
+0.9% +$95.5K 0.01% 869
2015
Q1 		$10.3M Buy
110,608
+1,658
+2% +$141K 0.01% 876
2014
Q4 		$9.69M Buy
108,950
+2,263
+2% +$165K 0.01% 879
2014
Q3 		$7.37M Buy
106,687
+4,372
+4% +$234K 0.01% 939
2014
Q2 		$5.87M Hold
102,315
– – 0.01% 996
2014
Q1 		$4.06M Buy
102,315
+1,843
+2% +$78.9K ﹤0.01% 1094
2013
Q4 		$4.22M Buy
100,472
+750
+0.8% +$21.7K ﹤0.01% 1041
2013
Q3 		$2.98M Buy
99,722
+95,159
+2,085% +$3.33M ﹤0.01% 1110
2013
Q2 		$242K Buy
+4,563
New +$200K ﹤0.01% 2151

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS AM's MACK Position: Q3 2017 in Review

UBS AM sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 13,633 shares — an estimated $133K sold.

UBS AM first reported a position in MACK in Q2 2013 and held it in 17 quarters. The position peaked at $11.1M in Q3 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • UBS AM reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • UBS AM sold 13,633 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $133K.
  • UBS AM first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 17 quarters.
  • UBS AM's Merrimack Pharmaceuticals, Inc. position peaked at $11.1M in Q3 2015.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on UBS AM's 13F filing for Q3 2017, filed 13 Nov 2017.